Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100 million wit...
AI-powered gap analysis, continuous compliance monitoring, real-time visibility, and pre-built life sciences frameworks help organizations reduce audit p...
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage spec...
The biopharmaceutical industry enters 2025 on strong footing, bolstered by scientific breakthroughs and a wave of digital innovation. In the post-AI market...
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has...
Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business...
The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging...
Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an...
Yatiri Bio Inc. announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at imp...
Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valu...
Esperion announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® ...
Kensana Health Inc. announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS ("GEM"), a Luxembourg...
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s...
© 2025 Biopharma Boardroom. All Rights Reserved.
